KatarinaLuptakovaMD

Hematology • Boston, MA

Hematologic Oncology

Instructor in Medicine, Beth Israel Deaconess Medical Center

Join to view full profile

Dr. Luptakova is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Luptakova's full profile

Already have an account?

Office
Caritas St Elizabeths Medical Center
736 Cambridge Street
Boston, MA 02135
Phone+1 617-789-3000

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
St Elizabeth's Medical CenterResidency, Internal Medicine, 2003 - 2006
Comenius UniversityClass of 2000

Certifications & Licensure

MA State Medical License 2006 - 2023

Clinical Trials

Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) Start of enrollment: 2011 Sep 01
Terminated
Phase 1
Lenalidomide After Allo Transplant Start of enrollment: 2012 Dec 01
Terminated
Phase 1
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma Start of enrollment: 2015 Dec 01
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

7 citations
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.
Alessandra Di Bacco, Nizar J. Bahlis, Nikhil C. Munshi, Hervé Avet-Loiseau, Tamás Masszi
European Journal of Haematology. 2020-03-07
322 citations
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N. Moore, Angeles Alvarez Secord, Melissa A. Geller, David Miller, N.G. Cloven
The Lancet. Oncology. 2019-05-01
8 citations
Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France
Huamao Mark Lin, Keith L. Davis, James A. Kaye, Katarina Luptakova, Saurabh P Nagar
Advances in Hematology. 2019-01-29

Press Mentions

The Courage of Patients in Phase 1 Cancer TrialsMay 31st, 2022